- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02081651
Parmigiano-Reggiano Cheese as a Possible Strategy to Acquire Oral Tolerance in Children With Cow's Milk Allergy
March 5, 2014 updated by: Roberto Berni Canani, Federico II University
Parmigiano-Reggiano Cheese as a Possible Strategy of Immunonutrition Able to Stimulate the Acquisition of Oral Tolerance in Childre With Cow's Milk Allergy
Cow's milk allergy is the most common food allergy in children.
The scenery clinical and epidemiological of cow's milk allergy is significantly changed in the last decade.
The severity of the clinical manifestations is still rising, and now cow's milk allergy has become the leading cause of hospitalization for food -induced anaphylaxis in our country.
In addition, the overall prevalence of cow's milk allergy is increasing for a gradual reduction in the ability to acquire immunological tolerance to cow's milk protein in the first years of life.
These mutations dictate the need to identify strategies to stimulate the acquisition of immunological tolerance in children affected by cow's milk allergy .
The mechanisms of acquired immunological tolerance are not yet fully defined .
The current view suggests the existence of a dynamic mechanism , consisting of various cellular compartments , which is set in a crucial environmental factors arising mainly from the diet and its effects on the intestinal microbiota.
These acquisitions have contributed to the definition of a new concept in the field of human nutrition: immunonutrition.
The immunonutrition is the ability, through the intake of specific nutrients on the immune system to interfere directly or indirectly through modulation of the composition and function of the intestinal microbiota.
The proponent group has recently shown that it is possible to stimulate a more rapid acquisition of immunological tolerance in children affected by CMA through the administration of extensively hydrolysed casein containing the probiotic Lactobacillus rhamnosus GG (LGG) (Berni Canani et al.
J Pediatr 2013) .
Several lines of evidence suggest that this effect is induced by a combination of direct immunomodulatory action exerted by some small peptides derived from the beta - casein and the action of lactobacillus GG.
It 's well known that the Lactobacillus GG is able to adjust the composition and functions of the microbiota in the child with CMA and directly adjust some immunological mechanisms involved in the pathogenesis of this condition.
At the same time other groups have demonstrated the possibility that a high percentage of patients with IgE-mediated CMA is able to tolerate foods containing hydrolyzed cow's milk proteins with different processes.
It has also been speculated that these strategies can facilitate the acquisition of immune tolerance in patients with cow's milk allergy.
One of these foods is Parmigiano -Reggiano cheese, which is characterized by an ' extensive hydrolysis of the proteins in cow's milk , which degrade the caseins present and generate large amounts of peptides and free amino acids and by the presence of appreciable quantities of Lactobacillus GG in the samples to maturing higher .
In a recent study it was shown that 58% of patients suffering from IgE-mediated CMA is able to tolerate a daily intake of normal amounts of this food , especially in the absence of a sensibilization to IgE specific to the beta lactoglobulin.
These new findings allow us to hypothesize the use of Parmigiano REggiano cheese as a possible strategy immunonutrition can stimulate the acquisition of immune tolerance in patients with CMA .
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
90
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 months to 6 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
-Children aged 3-10 years with cow's milk allergy
Exclusion Criteria:
- children aged less than 3 years or aged more than 10 years,
- concomitant chronic systemic diseases,
- active tubercolosis,
- autoimmune diseases,
- immunodeficiency,
- chronic inflammatory bowel disease,
- celiac disease,
- cystic fibrosis,
- metabolic diseases,
- malignancy,
- malformations of the gastrointestinal tract,
- suspected eosinophilic esophagitis or eosinophilic enterocolitis,
- suspected food-protien-induced enterocolitis syndrome,
- recent reaction to Parmigiano Reggiano cheese,
- pre/probiotic assumption
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Parmigiano Reggiano cheese
Children treated Parmigiano Reggiano cheese for 12 months
|
|
|
No Intervention: Control subjects
Children with cow's milk allergy not assuming Parmigiano Reggiano cheese
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of patients who acquire immunological tolerance to cow's milk
Time Frame: After 12 months of intervention
|
After 12 months of intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of patients with positive skin prick test with Parmigiano Reggiano cheese
Time Frame: Enrollment and after 12 months of dietary treatment
|
Enrollment and after 12 months of dietary treatment
|
|
Rate of patients able to tolerate the Parmigiano Reggiano cheese at enrollment
Time Frame: Enrollment
|
Enrollment
|
|
Differences in level of faecal butyrate after 12 months od treatment
Time Frame: After 12 months
|
After 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Anticipated)
September 1, 2015
Study Completion (Anticipated)
December 1, 2015
Study Registration Dates
First Submitted
February 27, 2014
First Submitted That Met QC Criteria
March 5, 2014
First Posted (Estimate)
March 7, 2014
Study Record Updates
Last Update Posted (Estimate)
March 7, 2014
Last Update Submitted That Met QC Criteria
March 5, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 272/13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.